Thinh H Nguyen
Overview
Explore the profile of Thinh H Nguyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nguyen T, Tran H, Thai T, La D, Tran H, Le K, et al.
Biomed Res Int
. 2020 Nov;
2020:1762151.
PMID: 33224972
Background: The choice of optimal treatment strategies for T4b colon cancers has still been discussed, particularly the initiation of neoadjuvant therapy or surgery. We conducted this study to evaluate the...
12.
Nguyen T, Makena M, Al-Rahawan M
J Pediatr Hematol Oncol
. 2020 Nov;
43(3):116.
PMID: 33165186
No abstract available.
13.
Makena M, Nguyen T, Koneru B, Hindle A, Chen W, Verlekar D, et al.
Anticancer Drugs
. 2020 Oct;
32(1):34-43.
PMID: 33079733
T-cell lymphoid malignancies (TCLMs) are in need of novel and more effective therapies. The histone deacetylase (HDAC) inhibitors and the synthetic cytotoxic retinoid fenretinide have achieved durable clinical responses in...
14.
Wei S, Nguyen T, Yang I, Mook D, Makena M, Verlekar D, et al.
Cell Death Dis
. 2020 May;
11(5):368.
PMID: 32409685
Despite the improvement in clinical outcome with 13-cis-retinoic acid (13-cisRA) + anti-GD2 antibody + cytokine immunotherapy given in first response ~40% of high-risk neuroblastoma patients die of recurrent disease. MYCN...
15.
Nguyen T, Makena M, Yavvari S, Kaur M, Pham T, Urias E, et al.
Medicina (Kaunas)
. 2020 May;
56(5).
PMID: 32392854
The majority of pediatric patients are cured of their primary cancer with current advanced developments in pediatric cancer therapy. However, survivors often experience long-term complications from therapies for primary cancer....
16.
Koneru B, Lopez G, Farooqi A, Conkrite K, Nguyen T, Macha S, et al.
Cancer Res
. 2020 Apr;
80(12):2663-2675.
PMID: 32291317
Neuroblastoma is a childhood cancer with heterogeneous clinical outcomes. To comprehensively assess the impact of telomere maintenance mechanism (TMM) on clinical outcomes in high-risk neuroblastoma, we integrated the C-circle assay...
17.
Nguyen T, Koneru B, Wei S, Chen W, Makena M, Urias E, et al.
Mol Cancer Ther
. 2019 Sep;
18(12):2270-2282.
PMID: 31484706
Recurrent high-risk neuroblastoma is a childhood cancer that often fails to respond to therapy. Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is...
18.
Nguyen T, Pham T, Strickland T, Brewer D, Belirgen M, Al-Rahawan M
Medicine (Baltimore)
. 2018 Oct;
97(39):e12477.
PMID: 30278534
Rationale: Hemangioblastoma is a rare tumor of the central nervous system (CNS). It is usually observed in patients with von-Hippel Lindau (VHL). The peak age for hemangioblastoma is between 20...
19.
Song M, Makena M, Hindle A, Koneru B, Nguyen T, Verlekar D, et al.
Anticancer Drugs
. 2018 Oct;
30(2):117-127.
PMID: 30272587
Objective: All-trans-N-(4-hydroxyphenyl)retinamide or fenretinide (4-HPR) acts by reactive oxygen species (ROS) and dihydroceramides (DHCers). In early-phase clinical trials 4-HPR has achieved complete responses in T-cell lymphomas (TCL) and neuroblastoma (NB)...
20.
Makena M, Cho H, Nguyen T, Koneru B, Verlekar D, Hindle A, et al.
Pediatr Blood Cancer
. 2018 Sep;
65(12):e27447.
PMID: 30251395
Background: Maintenance therapy with 13-cis-retinoic acid and immunotherapy (given after completion of intensive cytotoxic therapy) improves outcome for high-risk neuroblastoma patients. The synthetic retinoid fenretinide (4-HPR) achieved multiple complete responses...